Suresh K. Durgam is EVP, Chief Medical Officer of Intra-Cellular Therapies, Inc.. Currently has a direct ownership of 42,913 shares of ITCI, which is worth approximately $5.64 Million. The most recent transaction as insider was on Mar 10, 2025, when has been sold 3,116 shares (Common Stock) at a price of $131.24 per share, resulting in proceeds of $408,943. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 42.9K
116.7% 3M change
116.7% 12M change
Total Value Held $5.64 Million

Suresh K. Durgam Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 10 2025
SELL
Payment of exercise price or tax liability
$408,943 $131.24 p/Share
3,116 Reduced 6.77%
42,913 Common Stock
Mar 10 2025
BUY
Exercise of conversion of derivative security
-
7,345 Added 13.76%
46,029 Common Stock
Mar 06 2025
SELL
Payment of exercise price or tax liability
$730,990 $131.19 p/Share
5,572 Reduced 12.59%
38,684 Common Stock
Mar 06 2025
BUY
Exercise of conversion of derivative security
-
13,133 Added 22.88%
44,256 Common Stock
Mar 01 2025
SELL
Payment of exercise price or tax liability
$475,493 $128.2 p/Share
3,709 Reduced 10.65%
31,123 Common Stock
Mar 01 2025
BUY
Exercise of conversion of derivative security
-
8,742 Added 20.06%
34,832 Common Stock
Jan 31 2025
SELL
Payment of exercise price or tax liability
$600,710 $127.0 p/Share
4,730 Reduced 15.35%
26,090 Common Stock
Jan 31 2025
BUY
Grant, award, or other acquisition
-
11,017 Added 26.33%
30,820 Common Stock
Mar 11 2024
SELL
Open market or private sale
$244,880 $65.97 p/Share
3,712 Reduced 15.79%
19,803 Common Stock
Mar 10 2024
BUY
Exercise of conversion of derivative security
-
7,345 Added 23.8%
23,515 Common Stock
Mar 07 2024
SELL
Open market or private sale
$429,569 $66.6 p/Share
6,450 Reduced 28.51%
16,170 Common Stock
Mar 06 2024
BUY
Exercise of conversion of derivative security
-
13,132 Added 36.73%
22,620 Common Stock
Feb 26 2024
SELL
Open market or private sale
$288,621 $70.19 p/Share
4,112 Reduced 30.24%
9,488 Common Stock
Feb 23 2024
BUY
Exercise of conversion of derivative security
-
7,907 Added 36.76%
13,600 Common Stock
Feb 02 2024
SELL
Open market or private sale
$413,744 $67.09 p/Share
6,167 Reduced 52.0%
5,693 Common Stock
Feb 01 2024
BUY
Grant, award, or other acquisition
-
11,860 Added 50.0%
11,860 Common Stock
Jan 02 2024
SELL
Open market or private sale
$4,421,399 $70.99 p/Share
62,282 Reduced 100.0%
0 Common Stock
Jan 02 2024
BUY
Exercise of conversion of derivative security
$1,237,543 $19.87 p/Share
62,282 Added 50.0%
62,282 Common Stock
Dec 13 2023
SELL
Open market or private sale
$1,382,030 $65.0 p/Share
21,262 Reduced 100.0%
0 Common Stock
Jul 17 2023
SELL
Open market or private sale
$119,730 $65.0 p/Share
1,842 Reduced 7.97%
21,262 Common Stock
Mar 13 2023
SELL
Open market or private sale
$328,203 $44.69 p/Share
7,344 Reduced 24.12%
23,104 Common Stock
Mar 10 2023
BUY
Exercise of conversion of derivative security
-
7,344 Added 19.43%
30,448 Common Stock
Feb 24 2023
SELL
Open market or private sale
$372,688 $47.14 p/Share
7,906 Reduced 25.5%
23,104 Common Stock
Feb 23 2023
BUY
Exercise of conversion of derivative security
-
7,906 Added 20.32%
31,010 Common Stock
Feb 21 2023
SELL
Open market or private sale
$400,992 $48.0 p/Share
8,354 Reduced 26.56%
23,104 Common Stock
SKD

Suresh K. Durgam

EVP, Chief Medical Officer
New York, NY

Track Institutional and Insider Activities on ITCI

Follow Intra-Cellular Therapies, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ITCI shares.

Notify only if

Insider Trading

Get notified when an Intra Cellular Therapies, Inc. insider buys or sells ITCI shares.

Notify only if

News

Receive news related to Intra-Cellular Therapies, Inc.

Track Activities on ITCI